Hot flashes. Menopausal and female climacteric states
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Iranian and resident of Mashhad Literacy for reading and writing Phone number to call At least 12 months after the last normal menstruation or FSH> 40 and a maximum of one year after the last normal menstruation Healthy Pap smear: if the Pap smear is Liquid based from 5 years ago and the traditional Pap smear is from 3 years ago Complaints of hot flashes: on average during 2 weeks of screening, having moderate or severe hot flashes 5 or more times a day Not receiving estrogen or progesterone for the past three months No spotting in the past year Do not use tobacco (cigarettes, hookah and drugs) and alcohol No tragic events in life in the last 6 months: Death of spouse, children or close family members, severe illness of family members, major change in employment and life, dismissal or unemployment of self or spouse Severe family dispute or divorce Do not use medications to reduce the symptoms of hot flashes for the past 1 month: Hormonal contraceptives, venlafaxine, paroxytin, fluoxetine, gabapentin, clonidine, vitamin E supplements, bromocriptine, oral naloxone, veralipride, yoga, acupuncture, citalopram, sertraline, pre-gabapentin, relaxation techniques No chronic diseases: Cardiovascular, liver disorders, skin diseases, thyroid disorders Lack of sensitivity to Heracleum persicum: Includes any changes and skin allergies and sensitivity to sunlight Do not use medicinal plants containing phytoestrogens: including soybeans, flaxseed, licorice, fenugreek, fennel, hops, sage, red clover, black cohosh
Exclusion criteria
Exclusion criteria: Major changes in nutrition and physical activity patterns: Starting exercise programs Use of medicinal plants containing phytoestrogens during the study: including soybeans, flaxseed, licorice, fenugreek, fennel, hops, sage, red clover, black cohosh use medications to reduce the symptoms of hot flashes for the past 1 month: Hormonal contraceptives, venlafaxine, paroxytin, fluoxetine, gabapentin, clonidine, vitamin E supplements, bromocriptine, oral naloxone, veralipride, yoga, acupuncture, citalopram, sertraline, pre-gabapentin, relaxation techniques Do not fill out the hot flush questionnaire for 3 days or more in a week Do not take the drug for 2 days or more Occurrence of symptoms of allergy to heracleum persicum during the study: includes any changes and skin sensitivity and sensitivity to sunlight, including any changes and skin sensitivity and sensitivity to sunlight
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of hot flashes. Timepoint: At the beginning of the study and 2 and 4 weeks after the intervention. Method of measurement: Daily hot flush registration form.;Intensity of hot flashes. Timepoint: At the beginning of the study and 2 and 4 weeks after the intervention. Method of measurement: Daily hot flush registration form.;Frequent flushing. Timepoint: At the beginning of the study and 2 and 4 weeks after the intervention. Method of measurement: Daily hot flush registration form. | — |
Secondary
| Measure | Time frame |
|---|---|
| Intensity of night sweats. Timepoint: At the beginning of the study and 2 and 4 weeks after the intervention. Method of measurement: Night sweat registration form.;Frequent night sweats. Timepoint: At the beginning of the study and 2 and 4 weeks after the intervention. Method of measurement: Night sweat registration form. | — |
Countries
Iran (Islamic Republic of)
Contacts
Mashhad University of Medical Sciences